ME03417B - Jedinjenje pladienolid piridina i postupci primjene - Google Patents
Jedinjenje pladienolid piridina i postupci primjeneInfo
- Publication number
- ME03417B ME03417B MEP-2019-81A MEP201981A ME03417B ME 03417 B ME03417 B ME 03417B ME P201981 A MEP201981 A ME P201981A ME 03417 B ME03417 B ME 03417B
- Authority
- ME
- Montenegro
- Prior art keywords
- processes
- pyridine compounds
- pladienolide pyridine
- pladienolide
- compounds
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461993423P | 2014-05-15 | 2014-05-15 | |
| PCT/US2015/030464 WO2015175594A1 (en) | 2014-05-15 | 2015-05-13 | Pladienolide pyridine compounds and methods of use |
| EP15727125.5A EP3143016B1 (en) | 2014-05-15 | 2015-05-13 | Pladienolide pyridine compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03417B true ME03417B (me) | 2020-01-20 |
Family
ID=53284528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-81A ME03417B (me) | 2014-05-15 | 2015-05-13 | Jedinjenje pladienolid piridina i postupci primjene |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9481669B2 (me) |
| EP (2) | EP3514154B1 (me) |
| JP (1) | JP6067943B1 (me) |
| KR (2) | KR101710318B1 (me) |
| CN (1) | CN107074827B (me) |
| AR (1) | AR100431A1 (me) |
| AU (1) | AU2015259237B2 (me) |
| BR (1) | BR112016026638B1 (me) |
| CA (1) | CA2947754C (me) |
| CL (1) | CL2016002835A1 (me) |
| CY (1) | CY1121550T1 (me) |
| DK (1) | DK3143016T3 (me) |
| ES (1) | ES2712401T3 (me) |
| HR (1) | HRP20190432T1 (me) |
| HU (1) | HUE041838T2 (me) |
| IL (1) | IL248529B (me) |
| JO (1) | JO3668B1 (me) |
| LT (1) | LT3143016T (me) |
| MA (1) | MA39915B1 (me) |
| ME (1) | ME03417B (me) |
| MX (2) | MX388580B (me) |
| MY (1) | MY195081A (me) |
| PE (1) | PE20170384A1 (me) |
| PH (1) | PH12016502249B1 (me) |
| PL (1) | PL3143016T3 (me) |
| PT (1) | PT3143016T (me) |
| RS (1) | RS58400B1 (me) |
| RU (1) | RU2707730C2 (me) |
| SG (1) | SG11201609693XA (me) |
| SI (1) | SI3143016T1 (me) |
| SM (1) | SMT201900158T1 (me) |
| TR (1) | TR201902328T4 (me) |
| TW (1) | TWI634115B (me) |
| UA (1) | UA119458C2 (me) |
| WO (1) | WO2015175594A1 (me) |
| ZA (1) | ZA201607354B (me) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3344780B1 (en) | 2015-09-01 | 2021-06-23 | Eisai R&D Management Co., Ltd. | Splice variants associated with neomorphic sf3b1 mutants |
| SG10201913045PA (en) * | 2015-11-18 | 2020-02-27 | Eisai R&D Man Co Ltd | A solid state form of pladienolide pyridine compounds and methods of use |
| KR20190137810A (ko) * | 2017-03-15 | 2019-12-11 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 스플라이세오솜 돌연변이 및 그의 용도 |
| US11524009B2 (en) | 2017-10-31 | 2022-12-13 | Eisai R&D Management Co., Ltd. | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use |
| IL303335B2 (en) * | 2018-04-09 | 2025-01-01 | Eisai R&D Man Co Ltd | Palladianolide compounds and their uses |
| BR112020020956A2 (pt) * | 2018-04-12 | 2021-03-02 | Eisai R&D Management Co., Ltd. | derivados de pladienolida como spliceossoma que tem como alvo agentes para tratar câncer |
| KR20210016406A (ko) * | 2018-06-01 | 2021-02-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 스플라이싱 조정제를 사용하는 방법 |
| IL262658A (en) * | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
| WO2021248005A1 (en) * | 2020-06-05 | 2021-12-09 | Eisai R&D Management Co., Ltd. | Anti-bcma antibody-drug conjugates and methods of use |
| TW202233187A (zh) | 2020-11-04 | 2022-09-01 | 日商衛材R&D企管股份有限公司 | 骨髓發育不良症候群（ｍｄｓ）之生物標記物及其使用方法 |
| EP4361136A4 (en) * | 2021-06-18 | 2025-08-13 | Univ Cordoba | Compound for the treatment of glioblastoma |
| CN113876771B (zh) * | 2021-11-12 | 2022-09-23 | 中国医学科学院基础医学研究所 | 一种靶向pabpc1的小分子药物及其在慢性髓系白血病中的应用 |
| WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| CN119948022A (zh) | 2022-11-07 | 2025-05-06 | 卫材R&D管理有限公司 | 用于生产大环内酯类化合物的方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI312681B (en) | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
| TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| US7576204B2 (en) | 2002-07-31 | 2009-08-18 | Mercian Corporation | Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same |
| KR101285695B1 (ko) | 2002-07-31 | 2013-07-12 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신규한 생리 활성 물질 |
| WO2004037212A2 (en) | 2002-10-24 | 2004-05-06 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| NZ540103A (en) | 2002-11-29 | 2007-05-31 | Mercian Corp | Process for producing macrolide compound |
| KR20060110865A (ko) | 2003-11-27 | 2006-10-25 | 에자이 가부시키가이샤 | 매크로라이드계 화합물의 수산화에 관여하는 ｄｎａ |
| EP1702982B1 (en) | 2003-11-28 | 2010-05-05 | Kanagawa Academy Of Science And Technology | Method of detecting liver cancer, diagnostic for liver cancer and remedy for cancer |
| EP1764592A4 (en) | 2004-07-02 | 2009-08-19 | Plus One Techno & Co Ltd | COMBINED WEIGHING APPARATUS |
| CN1977046A (zh) | 2004-07-20 | 2007-06-06 | 卫材R&D管理有限公司 | 编码参与普拉地内酯生物合成的多肽的dna |
| TW200716744A (en) * | 2005-05-26 | 2007-05-01 | Eisai R&D Man Co Ltd | Genetically modified microorganism and process for production of macrolide compound using the microorganism |
| CN102010403A (zh) | 2005-10-13 | 2011-04-13 | 卫材R&D管理有限公司 | 普拉二烯内酯b和普拉二烯内酯d的全合成 |
| US20100021918A1 (en) * | 2007-03-05 | 2010-01-28 | Eisai R&D Management Co., Ltd. | Method for assaying action of antitumor agent using splicing defects as index |
| US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
-
2015
- 2015-05-13 CA CA2947754A patent/CA2947754C/en active Active
- 2015-05-13 KR KR1020167016648A patent/KR101710318B1/ko active Active
- 2015-05-13 ME MEP-2019-81A patent/ME03417B/me unknown
- 2015-05-13 JP JP2016526218A patent/JP6067943B1/ja active Active
- 2015-05-13 US US14/710,687 patent/US9481669B2/en active Active
- 2015-05-13 MY MYPI2016001944A patent/MY195081A/en unknown
- 2015-05-13 WO PCT/US2015/030464 patent/WO2015175594A1/en active Application Filing
- 2015-05-13 JO JOP/2015/0113A patent/JO3668B1/ar active
- 2015-05-13 ES ES15727125T patent/ES2712401T3/es active Active
- 2015-05-13 DK DK15727125.5T patent/DK3143016T3/en active
- 2015-05-13 RU RU2016148887A patent/RU2707730C2/ru active
- 2015-05-13 LT LTEP15727125.5T patent/LT3143016T/lt unknown
- 2015-05-13 PL PL15727125T patent/PL3143016T3/pl unknown
- 2015-05-13 UA UAA201612731A patent/UA119458C2/uk unknown
- 2015-05-13 AU AU2015259237A patent/AU2015259237B2/en active Active
- 2015-05-13 SI SI201530641T patent/SI3143016T1/sl unknown
- 2015-05-13 BR BR112016026638-2A patent/BR112016026638B1/pt active IP Right Grant
- 2015-05-13 AR ARP150101485A patent/AR100431A1/es active IP Right Grant
- 2015-05-13 SG SG11201609693XA patent/SG11201609693XA/en unknown
- 2015-05-13 PH PH1/2016/502249A patent/PH12016502249B1/en unknown
- 2015-05-13 SM SM20190158T patent/SMT201900158T1/it unknown
- 2015-05-13 PE PE2016002233A patent/PE20170384A1/es unknown
- 2015-05-13 KR KR1020177004442A patent/KR102146726B1/ko active Active
- 2015-05-13 MX MX2020004476A patent/MX388580B/es unknown
- 2015-05-13 EP EP18210019.8A patent/EP3514154B1/en active Active
- 2015-05-13 PT PT15727125T patent/PT3143016T/pt unknown
- 2015-05-13 TR TR2019/02328T patent/TR201902328T4/tr unknown
- 2015-05-13 HR HRP20190432TT patent/HRP20190432T1/hr unknown
- 2015-05-13 EP EP15727125.5A patent/EP3143016B1/en active Active
- 2015-05-13 TW TW104115293A patent/TWI634115B/zh active
- 2015-05-13 RS RS20190233A patent/RS58400B1/sr unknown
- 2015-05-13 HU HUE15727125A patent/HUE041838T2/hu unknown
- 2015-05-13 MX MX2016014997A patent/MX373324B/es active IP Right Grant
- 2015-05-13 CN CN201580025344.0A patent/CN107074827B/zh active Active
- 2015-05-13 MA MA39915A patent/MA39915B1/fr unknown
-
2016
- 2016-10-25 ZA ZA2016/07354A patent/ZA201607354B/en unknown
- 2016-10-26 IL IL24852916A patent/IL248529B/en active IP Right Grant
- 2016-11-08 CL CL2016002835A patent/CL2016002835A1/es unknown
-
2019
- 2019-02-22 CY CY20191100228T patent/CY1121550T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43827A (fr) | Composés di-nucléotides cycliques et leurs procédés d'utilisation | |
| MA39915A (fr) | Composés de pladiénolide pyridine et leurs procédés d'utilisation | |
| EP3504213A4 (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
| EP3429635A4 (en) | ANTI-CRISPR COMPOUNDS AND METHOD OF USE | |
| EP3359168A4 (en) | THERAPEUTIC COMPOUNDS AND METHOD | |
| MA49858A (fr) | Composés, compositions et procédés | |
| EP3380101A4 (en) | EIF4-A-INHIBITING COMPOUNDS AND METHODS THEREFOR | |
| MA49861A (fr) | Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation | |
| MA50063A (fr) | Composés, compositions et procédés | |
| MA43389A (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
| EP3337486A4 (en) | DEUTERIZED CONNECTIONS AND USES THEREOF | |
| RS60492B1 (sr) | Multipleksirani genomski inženjering omogućen pomoću crispr | |
| EP2968440A4 (en) | CYTOTOXIC AND ANTIMITOTIC COMPOUNDS AND METHOD FOR USE THEREOF | |
| MA53145A (fr) | Agents de liaison cd123 et leurs utilisations | |
| MA43205A (fr) | Composés pyy sélectifs et leurs utilisations | |
| EP3319610A4 (en) | OXYSTEROLS AND METHOD OF USE THEREOF | |
| EP3319612A4 (en) | OXYSTEROLS AND METHOD OF USE THEREOF | |
| PL3247791T3 (pl) | Uniwersalne komórki nkt | |
| EP3377060A4 (en) | PYRAZOL COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| EP3341027A4 (en) | TRANSFECTION COMPLEXES AND METHOD FOR USE THEREOF | |
| MA41296A (fr) | Procédés de transdifférenciation et procédés d'utilisation de ceux-ci | |
| DK3341303T3 (da) | Blisterpakning | |
| MA49560A (fr) | Composés cétoniques bicycliques et leurs procédés d'utilisation | |
| EP3156789C0 (en) | BIOSENSOR | |
| EP3303436A4 (en) | HYDROFLUOROLEFINES AND METHOD OF USE THEREOF |